Unknown OBSERVATIONAL NCT03430024

Nuclear Myosin VI - a Therapeutic Target in Breast Cancer

Nuclear Myosin VI - a Therapeutic Target in Estrogen Receptor Positive Breast Cancer?

Sponsor: Maidstone & Tunbridge Wells NHS Trust

Interventions Association of Myosin VI with oestrogen receptor

Updated 8 times since 2018 Last updated: Nov 11, 2019 Started: May 5, 2019 Primary completion: Dec 31, 2020 Completion: Dec 31, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Breast Cancer, this trial is ongoing. The trial is conducted by Maidstone & Tunbridge Wells NHS Trust and has accumulated 8 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Unknown
Jul 2024 — Sep 2024 [monthly]

Unknown

Status: Unknown Status → Unknown
Mar 2022 — Jul 2024 [monthly]

Unknown Status

Status: Recruiting → Unknown Status
Jan 2021 — Mar 2022 [monthly]

Recruiting
Dec 2019 — Jan 2021 [monthly]

Recruiting

Status: Not Yet Recruiting → Recruiting

▶ Show 3 earlier versions

Jun 2018 — Dec 2019 [monthly]

Not Yet Recruiting
Apr 2018 — Jun 2018 [monthly]

Not Yet Recruiting

Phase: NA → None
Mar 2018 — Apr 2018 [monthly]

Not Yet Recruiting NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Maidstone & Tunbridge Wells NHS Trust
University of Kent

Data source: Maidstone & Tunbridge Wells NHS Trust

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Maidstone, United Kingdom